XBRANE — Xbrane Biopharma AB Share News
0.000.00%
Last trade - 00:00- SEK235.93m
- SEK262.45m
- SEK152.35m
Brief: Xbrane Biopharma Q4 EBITDA Loss Narrows To SEK 28.2 Million
Brief: Xbrane Provides Update On Subsidiary Primm Pharma
Brief: Biogen, Xbrane Announce Commercialization And License Agreement For Proposed Biosimilar Referencing Cimzia
Brief: Xbrane Biopharma Q3 Loss For Period Narrows To SEK 45.5 Mln
Brief: Xbrane Announces Four More Patents Granted
Brief: Xbrane Granted Two Patents
Brief: Xbrane Biopharma, AGC Biologics Enter Into Agreement To Manufacture Xcimzane
Brief: Xbrane Biopharma Q2 EBITDA Loss At Sek 54.8 Million
Brief: Xbrane's Xlucane Meets Primary Endpoint In Pivotal Phase III Trial
Brief: Xbrane: Ambition To Generate Positive Operating Cash Flow Monthly By Late 2023/Early 2024
Brief: Xbrane Biopharma AB - Q1 Loss For Period Was Sek 51.3 mln
Brief: Xbrane Biopharma Q4 EBITDA Loss Widens To SEK 61.3 Mln
Brief: Xbrane Signs Non-Binding Term-Sheet On Sale Of Primm Pharma
Brief: Xbrane Appoints Anette Lindqvist As New CFO
Brief: Xbrane Re-Negotiates Pre-Existing IP License Agreement With Vaxiion Therapeutics
Brief: Xbrane Biopharma Q3 EBITDA Widens To SEK 55.8 Mln
Brief: Xbrane Biopharma Appoints New Interim CFO
Brief: Xbrane Biopharma Q2 EBITDA Loss Widens To SEK 51.6 Mln
Brief: Xbrane Biopharma AB - CFO Susanna Helgesen Leaves Xbrane